Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition

Dear Colleagues!

We are glad to present the 11^th Edition of the Standards of Specialized Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation.

The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO), International Diabetes Federation (IDF), European Association for the Study of Diabetes (EASD), American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), International Society for Pediatric and Adolescent Diabetes (ISPAD) and Russian Association of Endocrinologists (RAE). Current edition of the “Standards” also integrates results of completed randomized clinical trials, as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals.

Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 537 million patients by the end of 2021. According to the current estimation by the International Diabetes Federation, 643 million patients will be suffering from DM by 2030 and 783 million by 2045.

Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 962 762 patients with DM in this country on 01.01.2023 (3,42% of population) with 92,3% (4 581 990) – Type 2 DM, 5,6% (277 092) – Type 1 DM and 2,1% (103 680) – other types of DM, including 8 758 women with gestational DM. However, these results underestimate real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) confirmed that 54% of patients with Type 2 DM are undiagnosed. So real number of patients with DM in Russia is 11-12 million patients (about 7% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they don’t receive any treatment and have high risk of vascular complications.

Severe consequences of the global pandemic of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death.

In accordance with the Federal Law № 489-FZ of 25.12.2018 medical care should be provided on the basis of the clinical recommendations. Therefore, clinical recommendations posted in the rubricator of the Ministry of Health of the Russian Federation (https://cr.minzdrav.gov.ru) being the priority.

This edition of the Algorithms for Specialized Care for Patients with Diabetes Mellitus contains the main information from the clinical guidelines for the management of diabetes mellitus in adults and children (“Type 1 Diabetes in Children (2022)”, “Type 1 Diabetes in Adults (2022)”, “Type 2 diabetes mellitus in children (2021)”, “Type 2 diabetes mellitus in adults (2022)”), as well as the updated data.

New information has been added about indications for using of antihyperglycemic drugs and their instructional restrictions; algorithm of treatment of type 2 diabetes mellitus has been updated; clarifications have been made on the range of glycemic control in pregnant women; information on the treatment of diabetic complications and the management of pediatric patients has been added.

In 2023, Russian diabetology suffered an unbearable loss - Alexander Yuryevich Mayorov, who was the executive editor of the previous issues and an active participant of the work on all the previous editions of “Algorithms” from the moment they were founded, passed away. This publication is dedicated to the memory of Alexander Yuryevich, who was an example of the service to patients and medicine, a friend, teacher, mentor, generously sharing his knowledge and the sample of the execution of the medical duty to all of us.

 On behalf of the Working Group

1. Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). // Ожирение и метаболизм. — 2018. — Т.15. — № 1 — С.53-70. [Dedov II, Mel’nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism. 2018;15(1):53-70.] doi: 10.14341/OMET2018153-70

2. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» (10-й выпуск). Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. // Cахарный диабет. – 2021. –№1S – C. 1-148. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY (10th edition). Diabetes mellitus. 2021;24(1S):1-144.] doi.org/10.14341/DM12802

3. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Клинические рекомендации. Сахарный диабет 1 типа у взрослых (2022г). Доступно в рубрикаторе клинических рекомендаций МЗ РФ.

4. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Клинические рекомендации. Сахарный диабет 2 типа у взрослых (2022г). Доступно в рубрикаторе клинических рекомендаций МЗ РФ.

5. Майоров А.Ю., Мельникова О.Г., Котешкова О.М., Мисникова И.В., Черникова Н.А. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. ООО «АРТИНФО», Москва, 2018 – 64 с. [Mayorov AY, Melnikova OG, Koteshkova OM, Misnikoba IV, Chernikova NA. Tekhnika in’ektsiy I infuzii pri lechenii sakharnogo diabeta. Metodicheskoe rukovodstvo. OOO “ARTINFO”, Moscow, 2018 -64 p.].

6. Мустафина СВ, Рымар ОД, Сазонова ОВ, и др. Валидизация финской шкалы риска «FINDRISC» на европеоидной популяции Сибири. Сахарный диабет. 2016;19(2):113–118. doi: 10.14341/DM200418-10

7. Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров». Клинические рекомендации «Старческая астения». 2020. [Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskaya assotsiatsiya gerontologov i geriatrov”. Klinicheskie rekomendatsii “Starcheskaya asteniya”. 2020.]

8. Осложнения сахарного диабета: лечение и профилактика / Под ред. И.И. Дедова, М.В. Шестаковой. – М.: ООО «Издательство «Медицинское информационное агентство», 2017. [Dedov II, Shestakova MV, eds. Complications of diabetes mellitus: treatment and prevention. Moscow: Meditsinskoe informatsionnoe agentstvo; 2017].

9. Петеркова В.А., Безлепкина О.Б., Кураева Т.Л. и др. Клинические рекомендации. Сахарный диабет 2 типа у детей (2021). Доступно в рубрикаторе клинических рекомендаций МЗ РФ.

10. Петеркова В.А., Шестакова М.В., Безлепкина О.Б., и др. Клинические рекомендации. Сахарный диабет 1 типа у детей (2022). Доступно в рубрикаторе клинических рекомендаций МЗ РФ.

11. Потемкин В.В., Старостина Е.Г. Руководство по неотложной эндокринологии. – М: Медицинское информационное агентство, 2008. 393 с. [Potemkin VV, Starostina EG. Rukovodstvo po neotlozhnoy endokrinologii. Moscow: Meditsinskoe informatsionnoe agentstvo; 2008. 393p.].

12. Cахарный диабет типа 1: реалии и перспективы / Под ред. И.И. Дедова, М.В. Шестаковой. – М.: ООО «Издательство «Медицинское информационное агентство», 2016. [Dedov II, Shestakova MV, eds. Diabetes mellitus Type 1: reality and perspectives. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016].

13. Cахарный диабет типа 2: от теории к практике / Под ред. И.И. Дедова, М.В. Шестаковой. – М.: ООО «Издательство «Медицинское информационное агентство», 2016. [Dedov II, Shestakova MV, eds. Diabetes mellitus Type 2: from theory to practice. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016].

14. Cахарный диабет: многообразие клинических форм / Под ред. И.И. Дедова, М.В. Шестаковой. – М.: ООО «Издательство «Медицинское информационное агентство», 2016. [Dedov II, Shestakova MV, eds. Diabetes mellitus: andomizedy of clinical forms. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016].

15. Сахарный диабет и репродуктивная система / Под ред. И.И. Дедова, М.В. Шестаковой. – М.: ООО «Издательство «Медицинское информационное агентство», 2016. [Dedov II, Shestakova MV, eds. Diabetes mellitus and reproductive system. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016].

16. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. – М.: Медицинское информационное агентство, 2009. 500 с. [Shestakova MV, Dedov II. Diabetes mellitus and chronic kidney disease. Moscow: Meditsinskoe informatsionnoe agentstvo; 2009. 500 p.].

17. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J. 2018;39(9):763-816. Doi: 10.1093/eurheartj/ehx095

18. American Diabetes Association. Standards of medical care in diabetes – 2023. Diabetes Care. 2023;46(Suppl 1):S1-280.

19. de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98: S1–S115.

20. Busetto L et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10:597–632.

21. Classification of diabetes mellitus. World Health Organization. 2019.

22. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. Doi: 10.1093/eurheartj/ehaa575

23. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. Doi:10.1093/eurheartj/ehz486

24. Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61:257–264.

25. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640.

26. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-1966.

27. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006.

28. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization; 1999.

29. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. WHO Guideline. 2013.

30. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocr Pract. 2020;26(1):107-139. Doi: 10.4158/CS-2019-0472

31. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021;27(6):505-537. Doi: 10.1016/j.eprac.2021.04.008

32. Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021; 44(11):2589-2625. Doi.org/10.2337/dci21-0043

33. International Diabetes Federation. IDF Diabetes Atlas, 10 th edn. Brussels, Belgium: International Diabetes Federation, 2021.

34. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes in adolescence. Gregory JW, Cameron FJ, Joshi K, Eiswirth M, Garrett C, Garvey K, Agarwal S, Codner E.Pediatr Diabetes. 2022 Nov;23(7):857-871. doi: 10.1111/pedi.13408.

35. Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017;40(7):821-831. Doi: 10.2337/dc17-0291

36. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. Doi: 10.1056/NEJMoa1616011

37. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.

38. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi: 10.1056/NEJMoa1603827

39. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabøl R, Buse JB. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE-1. Am Heart J. 2016;179:175-83. Doi: 10.1016/j.ahj.2016.06.004

40. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12(3):164-74.

41. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicenter, randomized, double-blind trial. Lancet. 2019;394(10208):1519-1529. Doi: 10.1016/S0140-6736(19)32131-2

42. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Doi:10.1093/eurheartj/ehab368

43. Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220-34.e1-2. Doi: 10.1016/j.jvs.2013.08.003

44. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. Doi: 10.1056/NEJMoa1611925

45. Rubino F, Nathan DM, Eckel RH et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016;39:861–877.

46. Matthew C. Riddle, William T. Cefalu et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 1 October 2021; 44 (10): 2438–2444.

47. Schaper NC, Van Netten JJ, Apelqvist J, et al. Prevention and management of foot problems in diabetes: a Summary Guidance for Daily Practice 2015, based on the IWGDF Guidance Documents. Diabetes Metab Res Rev. 2016;(Suppl 1):7-15. Doi: 10.1002/dmrr.2695

48. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation (WHO/NMH/CHP/CPM/11.1). World Health Organization; 2011.

49. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. Doi:10.1093/eurheartj/ehab484

50. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018 Jan 9;137(2):119-129. Doi: 10.1161/CIRCULATIONAHA.117.028268

51. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. Doi: 10.1093/eurheartj/ehy339

52. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. Doi: 10.1056/NEJMoa1812389

53. World Union of Wound Healing Societies (WUWHS), Florence Congress, Position Document. Local management of diabetic foot ulcers. Wounds International, 2016.

54. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. Doi: 10.1056/NEJMoa1504720